Increased mental health care use by mothers of children with multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 31, 2019
- Accepted in final form September 8, 2019
- First Published January 9, 2020.
Article Versions
- Previous version (January 9, 2020 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Ruth Ann Marrie, MD, PhD,
- Julia O'Mahony, BSc,
- Colleen Maxwell, PhD,
- Vicki Ling, MSc,
- E. Ann Yeh, MD,
- Douglas L. Arnold, MD,
- Amit Bar-Or, MD,
- Brenda Banwell, MD;
- for the Canadian Pediatric Demyelinating Disease Network
- Ruth Ann Marrie, MD, PhD,
NONE
NONE
NONE
Multiple Sclerosis Journal, Editorial Board Multiple Sclerosis Journal-ETC, Co-Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Received support as principal investigator from the Canadian Institutes of Health Research (2010-2019), and Research Manitoba (2014-2019).
Waugh Family Chair in Multiple Sclerosis
Received support as principal investigator from Multiple Sclerosis Society of Canada (2009-2019) and the National Multiple Sclerosis Society (2013-2018), and as co-principal investigator from Multiple Sclerosis Scientific Foundation (2009-2019). Received support from Consortium of Multiple Sclerosis Centers (2004-2009, 2011-2014, 2016-2017), Crohn's and Colitis Canada (2014- 2019)
NONE
NONE
NONE
NONE
NONE
NONE
- Julia O'Mahony, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Colleen Maxwell, PhD,
NONE
NONE
NONE
Canadian Journal of Cardiology, Editorial Board Member, Nov 2007 to present. I have not received any compensation for my work on this board. Journal of Population Therapeutics and Clinical Pharmacology (formerly the Canadian Journal of Clinical Pharmacology), Associate Editor, May 2004 to present. I have not received any compensation for my work as an associate editor with this journal. Canadian Geriatrics Journal, Associate Editor, January 2014 to present. I have not received any compensation for my work on this board. Neuroepidemiology, Frontiers in Neurology, Review Editor, May 2019 - present. I have not received any compensation for my work on the editorial board.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Queen's University Dean's Research Fund, Co- investigator, 2019-2020. (2) CIHR and Partners, Phase Two of the Canadian Consortium on Neurodegeneration in Aging (CCNA), Co-investigator, 2019- 2024. (3) Multiple Sclerosis Society of Canada, Co-investigator, 2019-2022. (4) Ontario Brain Institute Integrated Discovery Program, ONDRI-2, Aim 4, Co-investigator, 2018-2023. (5) Velux Stiftung, Co-investigator, 2018-2020. (6) Canadian Frailty Network 2018 Catalyst Grant (Cat2018- 01), Co-investigator, 2018-2019. (7) Queen's University, Co-investigator, 2018-2020. (8) Canadian Frailty Network, CAT2017-21, Principal Investigator, 2018-2019. (9) CIHR Project Grant, Co-investigator, 2018-2021. (10) P.S.I. Foundation, Co-investigator, 2017-2019. (11) Ontario Ministry of Health and Long Term Care - Health System Research Fund Program Award, Co- investigator, 2017-2021. (12) CIHR Catalyst Grant, Co-investigator, 2017-2018. (13) Multiple Sclerosis Society of Canada Operating Research Grant, Co-investigator, 2017-2019. (14) Consortium of Multiple Sclerosis Centers (CMSC) Pilot Grant, Co-investigator, 2016-2017. (15) CIHR Program Grant, Co-investigator, 2016-2021. (16) Canadian Frailty Network/TVN Strategic Impact Grant, Co-PI, 2014-2017. (17) CIHR Project Grant, Principal Investigator, 2014- 2017. (18) CIHR Project Grant, Co-investigator, 2014-2017. (19) CIHR - Canadian Consortium on Neurodegeneration in Aging (CCNA) Team Grant, Co-investigator, 2014-2019.
(1) Queen's University (I am co-investigator on research grants being led by Dr. Dallas Seitz), 2018-2020. (2) Baycrest Centre for Geriatric Care (I am Co-investigator on Phase 2 of CCNA led by PI at Baycrest), 2019-2024. (3) University of Calgary (I am Co-investigator on several grants led by Dr. Kirsten Fiest), 2018-2021. (4) University of Waterloo (I am Co-investigator on several research grants), 2017-2020.
Physician Services Incorporated (P.S.I) Foundation. Multiple Sclerosis Scientific Research Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Vicki Ling, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- E. Ann Yeh, MD,
I perform MS relapse adjudication for ACI services on a fee-for-service basis. Juno therapeutics scientific advisory board 2017 Biogen, scientific advisory board 2019
NONE
NONE
Neurology, editorial advisory board, 2013-present. MSJ editorial board 2016-present BMC Neurology editorial board 2016-present PLOS-One: Editorial board, 2018-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen, funding for investigator-initiated research.
1) CIHR, Co-I. PI: Pohl 2) PCORI, Co-I, CE-1304-7079 3) CMSMS (CIHI/PHAC), MS Monitoring system pilot funding 4)SCN: co-PI, 2015-present 5)OIRM, co-PI, 2015-present, PI, 2019-present
NONE
1) National MS Society HC 0148 2) National MS Society PP2256 3) MS Society (Canada) 4) Dairy Farmers of Ontario 5) SickKids Innovation Fund 6) MS Research Foundation (Canada) 7) Rare Diseases Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Douglas L. Arnold, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Acorda Therapeutics, Biogen, Celgene, GeNeuro, Genentech, F. Hoffmann-La Roche, Merck, Novartis, Roche, Sanofi, Teva, Wave Life Sciences
NONE
NeuroRx Research, President
NONE
Biogen, Immunotec, Novartis
CIHR, MSSC
NONE
International Progressive MS Alliance
NONE
NONE
NONE
NONE
NONE
NONE
- Amit Bar-Or, MD,
Receptos-Celgene, Advisor, Scientific Board, 2011 - Sanofi/Genzyme, Advisor, Scientific board, 2017 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 - Guthy Jackson Greater Good Foundation, Scientific Advisor, 2008- Immune Tolerance Network - Steering Committee, 2016 -
NONE
Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-Genzyme 2015- GSK, Advisor 2012 - 2014
(1) Neurology, Editorial Board Member, 2008-2015 (2) Clinical and Experimental Neuroimmunology, Editorial Board Member, 2010 -
NONE
NONE
NONE
Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-genzyme - Advisor, 2015 - GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 -
NONE
NONE
NONE
(1) Novartis (2) Genzyme-Sanofi (3) Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brenda Banwell, MD;
Scientific Advisory Board, Biogen-IDEC, Sanofi, Eli Lilly, Novartis.
NONE
Novartis
I serve on the Editorial Board for Neurology. I receive no financial remuneration.
NONE
NONE
NONE
I have served as a consultant to Novartis.
I have spoken at an event supported by the Consortium of MS Centers, the Corpus, and Medscape
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis Society of Canada Multiple Sclerosis Scientific Research Foundation National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- for the Canadian Pediatric Demyelinating Disease Network
- From the Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg; Institute of Health Policy, Management and Evaluation (J.O.) and Division of Neurology, Neurosciences and Mental Health, SickKids Research Institute (E.A.Y.), The Hospital for Sick Children, University of Toronto; Schools of Pharmacy and Public Health and Health Systems (C.M.), University of Waterloo; ICES (C.M., V.L.), Toronto; Department of Pediatrics (E.A.Y.), University of Toronto; Montreal Neurological Institute (D.L.A.), McGill University, Montreal, Canada; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), Perelman School of Medicine, University of Pennsylvania; and Division of Child Neurology (B.B.), The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Correspondence
Dr. Marrie rmarrie{at}hsc.mb.ca
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Related Articles
- No related articles found.